13 completed, 7 recruiting, 4 unknown, 2 active not recruiting. 16 Phase 1, 13 Phase 2, 7 Phase 3, 1 Not applicable.
Follow Acute Myeloid Leukaemia: new trials by email Literature Review of Acute Myeloid Leukaemia trials Research Report on Acute Myeloid Leukaemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy IPN60340 + azacitidine + venetoclax, Placebo + azacitidine + venetoclax - Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia | Phase 2 / Phase 3 | Not yet recruiting | Ipsen | 540 | 2026-11-01 | 2026-09-10 |
| Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML AMX-883, Posaconazole - Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome | Phase 1 | Recruiting | Amphista Therapeutics Ltd | 54 | 2026-09-16 | 2026-10-15 |
| Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression AZD3632, Posaconazole - Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 85 | 2026-01-09 | 2026-10-23 |
| Clinical Study of U32 in Patients With Acute Myeloid Leukemia U32 CAR-T - Acute Myeloid Leukaemia | Phase 1 / Phase 2 | Recruiting | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 20 | 2025-07-03 | 2025-06-25 |
| Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation Early start post-transplant vaccination with Gardasil 9®, Late post-transplant vaccination with Gardasil 9® - Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated | Phase 2 | Recruiting | Vastra Gotaland Region | 100 | 2025-05-12 | 2025-06-05 |
| Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of Care Early palliative care integration - Palliative Care, Acute Myeloid Leukaemia | Not applicable | Not yet recruiting | Universidade do Porto | 50 | 2025-04-01 | 2025-02-27 |
| Leukemia Adapted Protocol Intensity-adapted pediatric acute myeloid treatment guidelines - Acute Myeloid Leukaemia | Recruiting | Baylor College of Medicine | 30 | 2025-01-01 | 2026-07-15 | |
| Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) Azacitidine, Onureg - Acute Myeloid Leukaemia | Phase 1 | Completed | Hikma Pharmaceuticals LLC | 32 | 2024-05-02 | 2025-09-26 |
| MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) mitoxantrone liposome, Ara-Cytarabine and azacitidine, Daunorubicin,Ara-Cytarabine, azacitidine - Acute Myeloid Leukaemia | Phase 3 | Recruiting | Zhongnan Hospital | 154 | 2024-01-18 | 2024-04-10 |
| A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia SAR445419, fludarabine, cytarabine - Acute Myeloid Leukaemia | Phase 1 | Terminated | Sanofi | 7 | 2023-06-16 | 2026-06-05 |
| GITMO AML/MDS-Relapse Registry Study Acute Myeloid Leukaemia, Myelodysplastic Syndrome | Completed | Gruppo Italiano Trapianto di Midollo Osseo | 859 | 2022-12-15 | 2025-01-28 | |
| Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation Monalizumab (anti-NKG2A monoclonal antibody) - Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Istituto Clinico Humanitas | 42 | 2021-12-03 | 2025-03-24 |
| Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia S 64315 (also referred as MIK665) and azacitidine - Acute Myeloid Leukaemia | Phase 1 / Phase 2 | Completed | Institut de Recherches Internationales Servier | 17 | 2021-02-17 | 2024-06-06 |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT Vyxeos, Fludarabine, Busulphan - Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome | Phase 2 / Phase 3 | Active not recruiting | University of Birmingham | 333 | 2020-01-27 | 2026-05-05 |
| Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia UCART123 - Acute Myeloid Leukaemia | Phase 1 | Withdrawn | Cellectis S.A. | 2019-07-11 | 2020-07-14 | |
| Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia. S 64315 (also referred as MIK665) and venetoclax - Acute Myeloid Leukaemia | Phase 1 | Completed | Institut de Recherches Internationales Servier | 37 | 2018-11-28 | 2024-02-05 |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. AZD2811, Azacitidine, Venetoclax - Acute Myeloid Leukaemia | Phase 1 | Terminated | AstraZeneca | 50 | 2017-07-31 | 2022-04-05 |
| International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia Gemtuzumab ozogamicin, Liposomal daunorubicin, Mitoxantrone - Acute Myeloid Leukaemia | Phase 3 | Active not recruiting | University of Birmingham | 700 | 2016-04-01 | 2026-06-29 |
| Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations Arm A Mylotarg plus DA Versus CPX-351, Arm B Vosaroxin and Decitabine, Arm D Small molecule or Not - Acute Myeloid Leukaemia, Myelodysplastic Syndrome | Phase 2 / Phase 3 | Unknown | Cardiff University | 1600 | 2014-10-30 | 2020-01-23 |
| Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation Partially HLA-matched unrelated donor cells - Acute Myeloid Leukaemia | Phase 1 | Unknown | University of Sydney | 12 | 2014-08-01 | 2015-11-02 |
Showing 20 of 31. Sign in to see all of them.
Leukemia, Myeloid, Acute (31) · Myelodysplastic Syndromes (6) · Anemia, Refractory, with Excess of Blasts (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Myeloproliferative Disorders (1) · Neoplasm, Residual (1) · Neoplasms (1)
Hematologic Diseases (31) · Hemic and Lymphatic Diseases (31) · Leukemia, Myeloid (31) · Neoplasms by Histologic Type (31) · Leukemia (30) · Neoplasms (30) · Bone Marrow Diseases (9) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphoproliferative Disorders (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3) · Lymphatic Diseases (3) · Anemia (2)
Azacitidine (5) · Cytarabine (5) · fludarabine (3) · venetoclax (3) · 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate (2) · Busulfan (2) · CPX-351 (2) · Gemtuzumab (2) · fludarabine phosphate (2) · posaconazole (2) · AZD2811 (1) · Clofarabine (1) · Cyclophosphamide (1) · Daunorubicin (1) · Decitabine (1)
AstraZeneca (4) · Cardiff University (2) · Institut de Recherches Internationales Servier (2) · University of Birmingham (2) · University of Leipzig (2) · Amphista Therapeutics Ltd (1) · Baylor College of Medicine (1) · Cell Medica Ltd (1) · Cellectis S.A. (1) · Gruppo Italiano Trapianto di Midollo Osseo (1) · Hikma Pharmaceuticals LLC (1) · Hospices Civils de Lyon (1) · Ipsen (1) · Istituto Clinico Humanitas (1) · Peter MacCallum Cancer Centre, Australia (1)
United Kingdom (9) · Australia (7) · United States (6) · France (4) · Germany (4) · Italy (3) · China (2) · Denmark (2) · Japan (2) · Canada (1) · Ireland (1) · Malawi (1) · New Zealand (1) · Portugal (1) · Saudi Arabia (1)
Alan K Burnett (1) · Brenda Gibson (1) · Casey McAtee, M.D., M.P.H. (1) · Charles Craddock, Professor (1) · Deborah S Richardson, MA MB BChir MD FRCP FRCPath (1) · Dietger Niederwieser, MD (1) · Dietger Niederwieser, Prof. (1) · Dr Kavita Raj (1) · Emma Morris, Dr (1) · Fuling Zhou (1) · Ghulam Mufti, Pr (1) · Howard Burris, MD (1) · Mathias Freund, MD (1)
PMID 22158386, PMID 22965967, PMID 41237344, PMID 41963545
2008 (1), 2014 (1), 2018 (1), 2019 (1), 2025 (1)